Segall Bryant & Hamill LLC purchased a new position in shares of ZimVie Inc. (NASDAQ:ZIMV - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 56,161 shares of the company's stock, valued at approximately $891,000. Segall Bryant & Hamill LLC owned approximately 0.20% of ZimVie as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors also recently added to or reduced their stakes in the company. Cetera Advisors LLC bought a new position in shares of ZimVie during the first quarter valued at approximately $2,615,000. Point72 Asset Management L.P. bought a new stake in shares of ZimVie in the 2nd quarter worth $3,993,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of ZimVie by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,531 shares of the company's stock valued at $356,000 after purchasing an additional 1,275 shares in the last quarter. First Eagle Investment Management LLC boosted its position in shares of ZimVie by 17.1% during the second quarter. First Eagle Investment Management LLC now owns 260,481 shares of the company's stock valued at $4,754,000 after buying an additional 38,124 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in ZimVie by 212.8% in the 2nd quarter. American Century Companies Inc. now owns 412,434 shares of the company's stock worth $7,527,000 after buying an additional 280,565 shares in the last quarter. Hedge funds and other institutional investors own 95.63% of the company's stock.
ZimVie Price Performance
Shares of NASDAQ ZIMV traded up $0.24 during midday trading on Monday, reaching $14.41. The stock had a trading volume of 123,611 shares, compared to its average volume of 307,396. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.38 and a current ratio of 1.94. The stock has a 50-day moving average of $14.83 and a 200-day moving average of $16.62. The company has a market capitalization of $397.72 million, a price-to-earnings ratio of -1.10 and a beta of 2.14. ZimVie Inc. has a 12-month low of $9.00 and a 12-month high of $22.40.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC lifted their price target on shares of ZimVie from $20.00 to $23.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd.
Read Our Latest Research Report on ZIMV
About ZimVie
(
Free Report)
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Featured Articles
Before you consider ZimVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ZimVie wasn't on the list.
While ZimVie currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
